Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503485 | 1.00 | TAAR1 (0.33) | TAAR1ELOVL1IDO1AGXTAOC3 | |
| SCHEMBL574575 | 0.84 | ADRB2 (0.35) | ELOVL1 | |
| SCHEMBL574831 | 0.84 | ADRB2 (0.35) | ELOVL1 | |
| SCHEMBL1245973 | 0.80 | ELOVL1 (0.41) | TAAR1ELOVL1IDO1AGXTAOC3 | |
| SCHEMBL3980398 | 0.77 | ALDH1A1 (0.39) | IDO1AGXT | |
| SCHEMBL3980397 | 0.77 | ALDH1A1 (0.39) | IDO1AGXT | |
| SCHEMBL503484 | 0.75 | TACR1 (0.33) | IDO1AOC3 | |
| SCHEMBL503097 | 0.75 | TACR1 (0.33) | IDO1AOC3 | |
| SCHEMBL574565 | 0.74 | TAAR1 (0.41) | TAAR1IDO1AGXTAOC3MAOB | |
| SCHEMBL574669 | 0.74 | TAAR1 (0.41) | TAAR1IDO1AGXTAOC3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132136-B2 | Pharmaceutical combination | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2600853-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016879-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | SEMINIS VEGETABLE SEEDS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TAAR1 1/4885ELOVL1 2221/4885IDO1 660/4885 |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TAAR1 1/4885ELOVL1 2221/4885IDO1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.